CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella, a biotechnology company pioneering transformative medicines for patients with severe conditions caused by disrupted amino acid biology, announced today that Robert Connelly, President and Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will take place March 8, 2017 at 11:30 a.m. EST.
About Amino Acids
Beyond their role as building blocks of
proteins, cell-specific sets of amino acids serve as regulators of
central metabolism and critical biological pathways. Axcella has
identified more than 2,000 diseases that are linked to amino acid
imbalances for which cells alone cannot compensate. The Axcella team
seeks to identify the optimal amino acid signature needed to
re-establish amino acid homeostasis in dysregulated cells for each
disease of focus.
About Axcella
Axcella is pioneering a revolutionary
therapeutic modality that identifies how disturbances in amino acid
biology lead to disease. The company’s platform rapidly yields novel
molecules to restore normal amino acid homeostasis, treat disease and
reactivate healthy central metabolism. Axcella has expeditiously
translated its discoveries into molecules that have been tested in 10
clinical trials to date, with lead programs in intractable epilepsy,
NASH and pathological atrophy. Its lead clinical candidates have
demonstrated in human and preclinical models an ability to bring
homeostasis to dysregulated cells, repair cellular function, restore
healthy pathways, and regenerate tissue and healthy organ function. The
company was founded by VentureLabs, the Innovation Foundry at Flagship
Pioneering, and has received financing from Flagship’s venture funds,
alongside co-investors Fidelity Research & Management Group, Gurnet
Point Capital and Nestlé Health Science. Axcella is based in Cambridge,
Mass. For more information, visit www.axcellahealth.com.
